ClinicaliQ Trial Snapshot
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis — Recruiting • Phase III • NCT07219420.
- Bimekizumab was tested against placebo in patients with palmoplantar pustulosis to assess its effectiveness and safety.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP). Conditions: Palmoplantar Pustulosis Interventions: Bimekizumab, Placebo Lead Sponsor: UCB Biopharma SRL Planned Enrollment: 320 participants